Targeting histone deacetylase 6 mediates a dual anti‐melanoma effect: Enhanced antitumor immunity and impaired cell proliferation

Targeting histone deacetylase 6 mediates a dual anti‐melanoma effect: Enhanced antitumor immunity and impaired cell proliferation

The median survival for metastatic melanoma is in the realm of 8–16 months and there are few therapies that offer significant improvement in overall survival. One of the recent advances in cancer treatment focuses on epigenetic modifiers to alter the survivability and immunogenicity of cancer cells....

Full description

Saved in:
Bibliographic Details
Main Authors: K.V. Woan, M. Lienlaf, P. Perez-Villaroel, C. Lee, F. Cheng, T. Knox, D.M. Woods, K. Barrios, J. Powers, E. Sahakian, H.W. Wang, J. Canales, D. Marante, K.S.M. Smalley, J. Bergman, E. Seto, A. Kozikowski, J. Pinilla-Ibarz, A. Sarnaik, E. Celis, J. Weber, E.M. Sotomayor, A. Villagra
Format: Article
Language:English
Published: Wiley 2015-08-01
Series:Molecular Oncology
Subjects:
Histone deacetylases
HDAC6
Melanoma
Nexturastat
Tubastatin A
Online Access:https://doi.org/10.1016/j.molonc.2015.04.002
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items